Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

Zhou C, Wei J, Xu K, Lin Y, Zhang L, Li X

Risk Management and Healthcare Policy 2023, 16:2447-2458

Published Date: 15 November 2023